Additionally, GLP-1 receptor agonists have demonstrated dual benefits in reducing headache symptoms and promoting weight loss in patients with idiopathic intracranial hypertension, offering therapeutic advantages for conditions involving both metabolic dysregulation and chronic pain63. Here, GLP1R is linked to pseudotumor cerebri.